Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Martin Sattler, Ph.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA134660 (SATTLER, MARTIN) Aug 7, 2008 - May 31, 2014
    NIH
    Reactive oxygen species and Genomic Instability in CML
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sattler M, Salgia R. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2022 Nov 03; JCO2202086. PMID: 36331252.
    Citations:    Fields:    
  2. Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2022 Oct 08; 14(19). PMID: 36230855; PMCID: PMC9562655.
    Citations: 1     
  3. Boytz R, Slabicki M, Ramaswamy S, Patten JJ, Zou C, Meng C, Hurst BL, Wang J, Nowak RP, Yang PL, Sattler M, Stone RM, Griffin JD, Gray NS, Gummuluru S, Davey RA, Weisberg E. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. J Med Virol. 2023 Jan; 95(1):e28157. PMID: 36117402; PMCID: PMC9538324.
    Citations:    Fields:    Translation:HumansCells
  4. Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, Thoma CR, Forrester W, Griffin JD. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 07 19; 12(7):110. PMID: 35853853; PMCID: PMC9296512.
    Citations:    Fields:    Translation:Humans
  5. Chen N, Golczer G, Ghose S, Lin B, Langenbucher A, Webb J, Bhanot H, Abt NB, Lin D, Varvares M, Sattler M, Egloff AM, Joh R, Uppaluri R, Emerick KS, Lawrence MS, Saladi SV. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4. Cell Rep. 2022 06 14; 39(11):110970. PMID: 35705032.
    Citations:    Fields:    Translation:HumansCells
  6. Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2022 Apr 01; 21(4):700. PMID: 35373301.
    Citations:    Fields:    
  7. Lapidot M, Saladi SV, Salgia R, Sattler M. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Front Pharmacol. 2021; 12:806570. PMID: 35069219; PMCID: PMC8776703.
    Citations:    
  8. Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia. 2021 Dec; 35(12):3628. PMID: 34489554.
    Citations:    Fields:    
  9. Yang J, Weisberg EL, Liu X, Magin RS, Chan WC, Hu B, Schauer NJ, Zhang S, Lamberto I, Doherty L, Meng C, Sattler M, Cabal-Hierro L, Winer E, Stone R, Marto JA, Griffin JD, Buhrlage SJ. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2022 01; 36(1):210-220. PMID: 34326465.
    Citations: 2     Fields:    Translation:HumansCells
  10. Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Muschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835. PMID: 34253596; PMCID: PMC8722383.
    Citations: 1     Fields:    Translation:HumansCells
  11. Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, Frank DA, Salgia R, Griffin JD, Saladi SV, Bueno R, Sattler M. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592. PMID: 34088988; PMCID: PMC8368004.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  12. Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia. 2021 12; 35(12):3509-3525. PMID: 34007044; PMCID: PMC8632680.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  13. Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186. PMID: 33521700; PMCID: PMC7817862.
    Citations: 17     Fields:    Translation:HumansCells
  14. Lapidot M, Case AE, Larios D, Gandler HI, Meng C, Tošic I, Weisberg EL, Poitras MJ, Gokhale PC, Paweletz CP, Podar K, Salgia R, Saladi SV, Griffin JD, Frank DA, Bueno R, Sattler M. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1). PMID: 33374980; PMCID: PMC7792575.
    Citations: 6     
  15. Reckamp KL, McQuerry JA, Mambetsariev I, Pharaon R, Yost SE, Fricke J, Mirzapoiazova T, Pillai RK, Khan Z, Fakih M, Yuan Y, Koczywas M, Massarelli E, Kulkarni P, Pal SK, Sattler M, Bild A, Salgia R. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Sci OA. 2020 Nov 25; 7(2):FSO662. PMID: 33437521.
    Citations:    
  16. Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543. PMID: 32144400.
    Citations:    Fields:    
  17. Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167. PMID: 32778962; PMCID: PMC7417114.
    Citations: 46     Fields:    Translation:HumansAnimalsPHPublic Health
  18. Weisberg E, Sattler M, Yang PL, Parent A, Gray N, Griffin JD. Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020 Aug; 98(8):483-489. PMID: 32640179.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  19. Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022. PMID: 32334240.
    Citations: 22     Fields:    Translation:HumansAnimals
  20. Mirzapoiazova T, Pozhitkov A, Nam A, Mambetsariev I, Nelson MS, Tan YC, Zhang K, Raz D, Singhal S, Nasser MW, Kulkarni P, Batra SK, Sattler M, Salgia R. Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. Int J Oncol. 2020 07; 57(1):80-86. PMID: 32236606.
    Citations: 1     Fields:    Translation:HumansCells
  21. Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, Adamia S, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184. PMID: 32015510; PMCID: PMC7156412.
    Citations: 8     Fields:    Translation:HumansCells
  22. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980. PMID: 31967735.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  23. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Toure AA, Buhrlage S, Liu X, Wang J, Gray N, Stone R, Adamia S, Winer E, Sattler M, Griffin JD. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156. PMID: 31943762.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  24. Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, Jolly MK, Kulkarni P, Salgia R. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. J Clin Med. 2019 Oct 18; 8(10). PMID: 31635338; PMCID: PMC6832522.
    Citations: 10     
  25. Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 2019 Sep 04; 8(9):49. PMID: 31484920.
    Citations: 10     
  26. Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629. PMID: 31455850.
    Citations: 6     Fields:    
  27. Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501. PMID: 31309543.
    Citations: 9     Fields:    Translation:HumansCells
  28. Vallet S, Fan F, Malvestiti S, Pecherstorfer M, Sattler M, Schneeweiss A, Schulze-Bergkamen H, Opferman JT, Cardone MH, Jäger D, Podar K. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast Cancer Res Treat. 2019 Feb; 173(3):585-596. PMID: 30374681.
    Citations: 5     Fields:    Translation:HumansCells
  29. Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M. Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget. 2018 May 25; 9(40):26226-26242. PMID: 29899855.
    Citations: 7     Fields:    
  30. Weisberg E, Sattler M, Manley PW, Griffin JD. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther. 2018; 11:175-182. PMID: 29343975; PMCID: PMC5749544.
    Citations: 2     
  31. Manley PW, Weisberg E, Sattler M, Griffin JD. Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. 2018 02 06; 57(5):477-478. PMID: 29188995; PMCID: PMC6295915.
    Citations: 4     Fields:    Translation:HumansCells
  32. Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984. PMID: 29299123.
    Citations: 7     Fields:    
  33. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215. PMID: 28967922; PMCID: PMC6314479.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  34. Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044. PMID: 28881711.
    Citations: 13     Fields:    
  35. Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06. PMID: 28706155.
    Citations:    
  36. Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650. PMID: 28978059.
    Citations: 11     Fields:    
  37. Sattler M, Salgia R. MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3. PMID: 27565402.
    Citations: 3     Fields:    Translation:Humans
  38. Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578. PMID: 27080907.
    Citations: 22     Fields:    Translation:HumansCells
  39. Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 2016 Feb 26; 18(1):26. PMID: 26921175; PMCID: PMC4769490.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  40. Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther. 2015 Oct; 14(10):2249-59. PMID: 26206331; PMCID: PMC4596780.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  41. Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015 May 14; 125(20):3133-43. PMID: 25833960; PMCID: PMC4432008.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  42. Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563. PMID: 25703587.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  43. Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95. PMID: 25186968.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  44. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014 Jun; 20(6):599-606. PMID: 24813251; PMCID: PMC4057660.
    Citations: 143     Fields:    Translation:Humans
  45. Weisberg E, Nonami A, Chen Z, Liu F, Zhang J, Sattler M, Nelson E, Cowens K, Christie AL, Mitsiades C, Wong KK, Liu Q, Gray N, Griffin JD. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37. PMID: 24791855.
    Citations: 29     Fields:    Translation:AnimalsCells
  46. Salgia R, Sattler M. A new hope for precision medicine. Sci Transl Med. 2013 Oct 23; 5(208):208fs38. PMID: 24154598.
    Citations:    Fields:    Translation:Humans
  47. Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. Cancer Lett. 2014 Feb 28; 343(2):286-94. PMID: 24120758.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  48. Toms AV, Deshpande A, McNally R, Jeong Y, Rogers JM, Kim CU, Gruner SM, Ficarro SB, Marto JA, Sattler M, Griffin JD, Eck MJ. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol. 2013 Oct; 20(10):1221-3. PMID: 24013208.
    Citations: 36     Fields:    Translation:HumansCells
  49. Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473. PMID: 23437141.
    Citations: 23     Fields:    Translation:HumansCells
  50. Weisberg E, Sattler M. A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3. Haematologica. 2012 Nov; 97(11):1620-1. PMID: 23125243.
    Citations: 2     Fields:    Translation:Humans
  51. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44. PMID: 22469781.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  52. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012 May 03; 119(18):4253-63. PMID: 22411871; PMCID: PMC3359741.
    Citations: 70     Fields:    Translation:HumansAnimalsCells
  53. Reddy MM, Deshpande A, Sattler M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets. 2012 Mar; 16(3):313-24. PMID: 22339244.
    Citations: 11     Fields:    Translation:Humans
  54. Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351. PMID: 21980431.
    Citations: 17     Fields:    Translation:HumansCells
  55. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011 Nov; 155(4):438-48. PMID: 21923653.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  56. Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, Sattler M. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012 Apr; 26(4):708-15. PMID: 21926964; PMCID: PMC3974504.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  57. Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M. The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012 Mar; 26(3):481-9. PMID: 21860432.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  58. Talbot AL, Bullock GC, Delehanty LL, Sattler M, Zhao ZJ, Goldfarb AN. Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling. PLoS One. 2011; 6(8):e23850. PMID: 21887333.
    Citations: 7     Fields:    Translation:AnimalsCells
  59. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol. 2011 Jul; 3(4):171-84. PMID: 21904579.
    Citations: 48     
  60. Lutz V, Sattler M, Gallinat S, Wenck H, Poertner R, Fischer F. Impact of collagen crosslinking on the second harmonic generation signal and the fluorescence lifetime of collagen autofluorescence. Skin Res Technol. 2012 May; 18(2):168-79. PMID: 21564311.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  61. Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M, Raja SM, Natarajan A, Band V, Band H. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget. 2011 Mar; 2(3):245-50. PMID: 21422499.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  62. Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9. PMID: 21072051.
    Citations: 59     Fields:    Translation:HumansAnimalsCells
  63. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010 Sep 16; 29(37):5120-34. PMID: 20622902.
    Citations: 42     Fields:    Translation:HumansCells
  64. Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605. PMID: 20622007.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  65. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972. PMID: 20126411.
    Citations: 56     Fields:    Translation:HumansCells
  66. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7. PMID: 20018760.
    Citations: 134     Fields:    Translation:HumansCells
  67. Sattler M, Griffin JD. JAK2 gets histone H3 rolling. Cancer Cell. 2009 Nov 06; 16(5):365-6. PMID: 19878867.
    Citations: 5     Fields:    Translation:HumansCells
  68. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23. PMID: 19723643; PMCID: PMC2767337.
    Citations: 91     Fields:    Translation:Humans
  69. Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD, Weinstock DM, Sattler M. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9. PMID: 19571320; PMCID: PMC2738569.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  70. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC, Podar K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009 Jun 15; 69(12):5082-90. PMID: 19509231.
    Citations: 41     Fields:    Translation:HumansAnimalsCells
  71. Sattler M, Salgia R. The MET axis as a therapeutic target. Update Cancer Ther. 2009 Apr 01; 3(3):109-118. PMID: 20368753.
    Citations: 18     
  72. Rodrigues MS, Reddy MM, Sattler M. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal. 2008 Oct; 10(10):1813-48. PMID: 18593226.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  73. Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19. PMID: 18836658.
    Citations: 9     Fields:    Translation:Humans
  74. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 01; 111(7):3751-9. PMID: 18216297; PMCID: PMC2275031.
    Citations: 62     Fields:    Translation:HumansAnimalsCells
  75. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42. PMID: 18172305; PMCID: PMC2767335.
    Citations: 63     Fields:    Translation:HumansAnimals
  76. Rodrigues MS, Sattler M. Chronic myelogenous leukemia progenitors display a genetically unstable personality. J Natl Cancer Inst. 2007 May 02; 99(9):662-3. PMID: 17470729.
    Citations:    Fields:    Translation:HumansCells
  77. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007 Mar; 9(2):102-8. PMID: 17288874.
    Citations: 51     Fields:    Translation:HumansAnimals
  78. Podar K, Raab MS, Tonon G, Sattler M, Barilà D, Zhang J, Tai YT, Yasui H, Raje N, DePinho RA, Hideshima T, Chauhan D, Anderson KC. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007 Feb 15; 67(4):1680-8. PMID: 17308109.
    Citations: 35     Fields:    Translation:HumansCells
  79. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83. PMID: 17164332; PMCID: PMC1748251.
    Citations: 75     Fields:    Translation:HumansAnimalsCells
  80. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006 Jun 30; 281(26):18177-83. PMID: 16632470.
    Citations: 39     Fields:    Translation:HumansCells
  81. Sattler M, Walz C, Crowley BJ, Lengfelder E, Jänne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 01; 107(3):1237-8. PMID: 16434495; PMCID: PMC1895916.
    Citations: 4     Fields:    Translation:Humans
  82. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol. 2006 Feb; 57(2):145-64. PMID: 16213151.
    Citations: 28     Fields:    Translation:Humans
  83. Sattler M. Inside Blood: How to interfere with FLT3. Blood. 2005; 105:2625-2626.
  84. Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6. PMID: 15492276.
    Citations: 23     Fields:    Translation:HumansCells
  85. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23. PMID: 15486067.
    Citations: 94     Fields:    Translation:HumansCells
  86. Banerji L, Sattler M. Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. Expert Opin Ther Targets. 2004 Jun; 8(3):221-39. PMID: 15161429.
    Citations: 7     Fields:    Translation:HumansAnimals
  87. Sattler M, Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leuk Res. 2004 May; 28 Suppl 1:S11-20. PMID: 15036937.
    Citations: 18     Fields:    Translation:HumansCells
  88. Podar K, Mostoslavsky G, Sattler M, Tai YT, Hayashi T, Catley LP, Hideshima T, Mulligan RC, Chauhan D, Anderson KC. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65. PMID: 15010462.
    Citations: 24     Fields:    Translation:HumansCells
  89. Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res. 2004; 119:121-38. PMID: 15164876.
    Citations: 10     Fields:    Translation:HumansAnimals
  90. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81. PMID: 14559814.
    Citations: 192     Fields:    Translation:HumansAnimalsCells
  91. Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KC. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300. PMID: 13679868.
    Citations: 17     Fields:    Translation:HumansCells
  92. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003 Sep 01; 63(17):5462-9. PMID: 14500382.
    Citations: 83     Fields:    Translation:AnimalsCells
  93. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr; 40(2 Suppl 2):4-10. PMID: 12783368.
    Citations: 51     Fields:    Translation:HumansCells
  94. Sattler M, Quinnan LR, Pride YB, Gramlich JL, Chu SC, Even GC, Kraeft SK, Chen LB, Salgia R. 2-methoxyestradiol alters cell motility, migration, and adhesion. Blood. 2003 Jul 01; 102(1):289-96. PMID: 12637335.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  95. Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71. PMID: 12635090.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  96. Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40. PMID: 12908554.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  97. Sattler M, Quackenbush E, Salgia R. Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases. Methods Mol Med. 2003; 85:87-105. PMID: 12710200.
    Citations: 2     Fields:    Translation:HumansAnimals
  98. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801. PMID: 12482878.
    Citations: 35     Fields:    Translation:HumansCells
  99. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11. PMID: 12414661.
    Citations: 79     Fields:    Translation:HumansCells
  100. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94. PMID: 12200384.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  101. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92. PMID: 12124177.
    Citations: 119     Fields:    Translation:HumansAnimalsCells
  102. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33. PMID: 11857085.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  103. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81. PMID: 11751905.
    Citations: 48     Fields:    Translation:HumansCells
  104. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001 Jul 15; 98(2):428-35. PMID: 11435313.
    Citations: 87     Fields:    Translation:HumansCells
  105. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 Apr; 73(3):278-91. PMID: 11345193.
    Citations: 24     Fields:    Translation:HumansCells
  106. Sattler M, Verma S, Pride YB, Salgia R, Rohrschneider LR, Griffin JD. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8. PMID: 11031258.
    Citations: 17     Fields:    Translation:AnimalsCells
  107. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8. PMID: 10833515.
    Citations: 116     Fields:    Translation:HumansAnimalsCells
  108. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8. PMID: 10918610.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  109. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25. PMID: 10706883.
    Citations: 59     Fields:    Translation:AnimalsCells
  110. Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog. 2000; 11(1):63-76. PMID: 10795627.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  111. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, Griffin JD. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46. PMID: 10590068.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  112. Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, Algate PA, Rohrschneider LR, Griffin JD. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999 Nov; 19(11):7473-80. PMID: 10523635.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  113. Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35. PMID: 10216087.
    Citations: 77     Fields:    Translation:HumansAnimalsCells
  114. Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77. PMID: 9926921.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  115. Christians U, Sewing KF, Sattler M. Rapamycin metabolites. 1998.
  116. Sattler M, Salgia R. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia. 1998 May; 12(5):637-44. PMID: 9593259.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  117. Griffin JD, Sattler M, Uemura N, Okuda K, Salgia R. . Transformation of myeloid cells by the BCR/ABL oncogene. Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Kaeting M, Plunkett W (eds.) Acute Leukemia VII, Experimental Approaches and Novel Therapies. 1998; 182-189.
  118. Sattler M, Salgia R, Shrikhande G, Verma S, Choi JL, Rohrschneider LR, Griffin JD. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 06; 15(19):2379-84. PMID: 9393882.
    Citations: 14     Fields:    Translation:AnimalsCells
  119. Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57. PMID: 9202056; PMCID: PMC508164.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  120. Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, Griffin JD. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6. PMID: 9162067.
    Citations: 25     Fields:    Translation:HumansCells
  121. Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11; 272(15):10248-53. PMID: 9092574.
    Citations: 31     Fields:    Translation:HumansCells
  122. Sattler M, Salgia R, Durstin MA, Prasad KV, Griffin JD. Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33. PMID: 9119889.
    Citations: 8     Fields:    Translation:AnimalsCells
  123. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 1997 Mar; 8(1):63-79. PMID: 9174663.
    Citations: 15     Fields:    Translation:HumansCells
  124. Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85. PMID: 9067577.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  125. Manié SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6. PMID: 9020138.
    Citations: 38     Fields:    Translation:HumansCells
  126. Manié SN, Sattler M, Astier A, Phifer JS, Canty T, Morimoto C, Druker BJ, Salgia R, Griffin JD, Freedman AS. Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50. PMID: 8989906.
    Citations: 6     Fields:    Translation:HumansCells
  127. Weisberg E, Sattler M, Ewaniuk DS, Salgia R. Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog. 1997; 8(4):343-58. PMID: 9622054.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  128. Salgia R, Avraham S, Pisick E, Li JL, Raja S, Greenfield EA, Sattler M, Avraham H, Griffin JD. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6. PMID: 8940124.
    Citations: 34     Fields:    Translation:AnimalsCells
  129. Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203. PMID: 8810278.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  130. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46. PMID: 8632906.
    Citations: 52     Fields:    Translation:HumansCells
  131. Salgia R, Sattler M, Pisick E, Li JL, Griffin JD. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb; 24(2):310-3. PMID: 8641358.
    Citations: 9     Fields:    Translation:HumansCells
  132. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem. 1995 Dec 08; 270(49):29145-50. PMID: 7493940.
    Citations: 26     Fields:    Translation:HumansCells
  133. Sattler M, Durstin MA, Frank DA, Okuda K, Kaushansky K, Salgia R, Griffin JD. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8. PMID: 7543416.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  134. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992 Sep-Oct; 20(5):753-61. PMID: 1385058.
    Citations: 83     Fields:    Translation:HumansAnimals
  135. Sattler M. Cytochrome 450-dependent extrahepatic metabolism of the immunosuppressive macrolides Rapamycin and FK506 as well as the undecapeptide Cyclosporine (German). 1992.
  136. Christians U, Sattler M, Schiebel HM, Kruse C, Radeke HH, Linck A, Sewing KF. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 1992 Mar-Apr; 20(2):186-91. PMID: 1352208.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  137. Christians U, Braun F, Sattler M, Almeidal VM, Linck A, Sewing KF. Interactions of FK 506 and cyclosporine metabolism. Transplant Proc. 1991 Dec; 23(6):2794-6. PMID: 1721280.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  138. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, Schottmann R, Linck A, Almeida VM, Braun F, et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant Proc. 1991 Feb; 23(1 Pt 2):940-1. PMID: 1703358.
    Citations: 18     Fields:    Translation:Humans
  139. Sattler M. Possible interleukin 1 induced signaling mechanism in murine EL4-6.1 thymoma cells (German). 1989.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Sattler's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (507)
Explore
_
Co-Authors (65)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.